Warning: The NCBI web site requires JavaScript to function. more...

PubMed

US National Library of Medicine National Institutes of Health

RSS
RSS Settings
- Search: Palmitoylethanolamide
- Number of items displayed:
- Feed name:
Save search
Advanced
Help

We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

<< First< Prev

Page of 18

Next >Last >>

Results: 1 to 20 of 354

Select item 236704901.

Elevated brain cannabinoid CB₁ receptor availability in post-traumatic stress disorder: a positron emission tomography study.

Neumeister A, Normandin MD, Pietrzak RH, Piomelli D, Zheng MQ, Gujarro-Anton A, Potenza MN, Bailey CR, Lin SF, Najafzadeh S, Ropchan J, Henry S, Corsi-Travali S, Carson RE, Huang Y.

Mol Psychiatry. 2013 May 14. doi: 10.1038/mp.2013.61. [Epub ahead of print]

PMID:: 23670490; [PubMed - as supplied by publisher]

Related citations

Select item 236675162.

Plasma concentrations of endocannabinoids and related primary Fatty Acid amides in patients with post-traumatic stress disorder.

Hauer D, Schelling G, Gola H, Campolongo P, Morath J, Roozendaal B, Hamuni G, Karabatsiakis A, Atsak P, Vogeser M, Kolassa IT.

PLoS One. 2013 May 7;8(5):e62741. doi: 10.1371/journal.pone.0062741. Print 2013.

PMID:: 23667516; [PubMed - in process]

Free Article

Related citations

Select item 236584933.

Treatment of chronic regional pain syndrome type 1 with palmitoylethanolamide and topical ketamine cream: modulation of nonneuronal cells.

Keppel Hesselink JM, Kopsky DJ.

J Pain Res. 2013 Mar 21;6:239-45. doi: 10.2147/JPR.S42417. Print 2013.

PMID:: 23658493; [PubMed]

Free PMC Article

Related citations

Select item 236436924.

Alterations in the endocannabinoid system in the rat valproic acid model of autism.

Kerr DM, Downey L, Conboy M, Finn DP, Roche M.

Behav Brain Res. 2013 May 1. doi:pii: S0166-4328(13)00251-9. 10.1016/j.bbr.2013.04.043. [Epub ahead of print]

PMID:: 23643692; [PubMed - as supplied by publisher]

Related citations

Select item 236163055.

Circulating endocannabinoids in insulin sensitive vs. Insulin resistant obese postmenopausal women. A MONET group study.

Abdulnour J, Yasari S, Rabasa-Lhoret R, Faraj M, Petrosino S, Piscitelli F, Prud'homme D, Di Marzo V.

Obesity (Silver Spring). 2013 Apr 24. doi: 10.1002/oby.20498. [Epub ahead of print]

PMID:: 23616305; [PubMed - as supplied by publisher]

Related citations

Select item 235817076.

Emerging Neuroprotective Effects of N-Palmitoylethanolamide Besides Its Significant Antinociceptive Effects.

Kapoor S.

Pain Med. 2013 Apr 12. doi: 10.1111/pme.12118. [Epub ahead of print] No abstract available.

PMID:: 23581707; [PubMed - as supplied by publisher]

Related citations

Select item 235782187.

Platelet Rich Plasma exerts anti-nociceptive activity by a peripheral endocannabinoid-related mechanism.

Descalzi F, Ulivi V, Cancedda R, Piscitelli F, Luongo L, Guida F, Gatta L, Maione S, Di Marzo V.

Tissue Eng Part A. 2013 Apr 12. [Epub ahead of print]

PMID:: 23578218; [PubMed - as supplied by publisher]

Related citations

Select item 235732308.

Full Inhibition of Spinal FAAH Leads to TRPV1-Mediated Analgesic Effects in Neuropathic Rats and Possible Lipoxygenase-Mediated Remodeling of Anandamide Metabolism.

Starowicz K, Makuch W, Korostynski M, Malek N, Slezak M, Zychowska M, Petrosino S, De Petrocellis L, Cristino L, Przewlocka B, Di Marzo V.

PLoS One. 2013;8(4):e60040. doi: 10.1371/journal.pone.0060040. Epub 2013 Apr 3.

PMID:: 23573230; [PubMed - in process]

Free PMC Article

Related citations

Select item 235333049.

Palmitoylethanolamide is a disease-modifying agent in peripheral neuropathy: pain relief and neuroprotection share a PPAR-alpha-mediated mechanism.

Di Cesare Mannelli L, D'Agostino G, Pacini A, Russo R, Zanardelli M, Ghelardini C, Calignano A.

Mediators Inflamm. 2013;2013:328797. doi: 10.1155/2013/328797. Epub 2013 Feb 25.

PMID:: 23533304; [PubMed - in process]

Free PMC Article

Related citations

Select item 2348637310.

[Administration of MICRONIZED PALMITOYLETHANOLAMIDE (PEA)-transpolydatin in the treatment of chronic pelvic pain in women affected by endometriosis: preliminary results.]

Lo Monte G, Soave I, Marci R.

Minerva Ginecol. 2013 Mar 13. [Epub ahead of print] Italian.

PMID:: 23486373; [PubMed - as supplied by publisher]

Related citations

Select item 2342557511.

Metabolism of endocannabinoids and related N-acylethanolamines: Canonical and alternative pathways.

Ueda N, Tsuboi K, Uyama T.

FEBS J. 2013 May;280(9):1874-94. doi: 10.1111/febs.12152. Epub 2013 Feb 21.

PMID:: 23425575; [PubMed - in process]

Related citations

Select item 2341457812.

Evidence for a role of GABAergic and glutamatergic signalling in the basolateral amygdala in endocannabinoid-mediated fear-conditioned analgesia in rats.

Rea K, Olango WM, Harhen B, Kerr DM, Galligan R, Fitzgerald S, Moore M, Roche M, Finn DP.

Pain. 2013 Apr;154(4):576-85. doi: 10.1016/j.pain.2012.12.021. Epub 2012 Dec 31.

PMID:: 23414578; [PubMed - in process]

Related citations

Select item 2339892113.

Taste sensitivity to 6-n-propylthiouracil is associated with endocannabinoid plasma levels in normal-weight individuals.

Tomassini Barbarossa I, Carta G, Murru E, Melis M, Zonza A, Vacca C, Muroni P, Di Marzo V, Banni S.

Nutrition. 2013 Mar;29(3):531-6. doi: 10.1016/j.nut.2012.09.018.

PMID:: 23398921; [PubMed - in process]

Related citations

Select item 2339452814.

Measurement of palmitoylethanolamide and other N-acylethanolamines during physiological and pathological conditions.

Balvers MG, Verhoeckx KC, Meijerink J, Wortelboer HM, Witkamp RF.

CNS Neurol Disord Drug Targets. 2013 Feb 1;12(1):23-33.

PMID:: 23394528; [PubMed - in process]

Related citations

Select item 2339452715.

Biosynthetic pathways of bioactive N-acylethanolamines in brain.

Tsuboi K, Ikematsu N, Uyama T, Deutsch DG, Tokumura A, Ueda N.

CNS Neurol Disord Drug Targets. 2013 Feb 1;12(1):7-16.

PMID:: 23394527; [PubMed - in process]

Related citations

Select item 2339452616.

Neuroglial roots of neurodegenerative diseases: therapeutic potential of palmitoylethanolamide in models of Alzheimer's disease.

Scuderi C, Steardo L.

CNS Neurol Disord Drug Targets. 2013 Feb 1;12(1):62-9.

PMID:: 23394526; [PubMed - in process]

Related citations

Select item 2339452517.

Physiological role of peroxisome proliferator-activated receptors type alpha on dopamine systems.

Melis M, Carta G, Pistis M, Banni S.

CNS Neurol Disord Drug Targets. 2013 Feb 1;12(1):70-7.

PMID:: 23394525; [PubMed - in process]

Related citations

Select item 2339452418.

Palmitoylethanolamide reduces formalin-induced neuropathic-like behaviour through spinal glial/microglial phenotypical changes in mice.

Luongo L, Guida F, Boccella S, Bellini G, Gatta L, Rossi F, de Novellis V, Maione S.

CNS Neurol Disord Drug Targets. 2013 Feb 1;12(1):45-54.

PMID:: 23394524; [PubMed - in process]

Related citations

Select item 2339452319.

New insights in mast cell modulation by palmitoylethanolamide.

De Filippis D, Negro L, Vaia M, Cinelli MP, Iuvone T.

CNS Neurol Disord Drug Targets. 2013 Feb 1;12(1):78-83.

PMID:: 23394523; [PubMed - in process]

Related citations

Select item 2339452220.

Effect of diet on tissue levels of palmitoylethanolamide.

Hansen HS.

CNS Neurol Disord Drug Targets. 2013 Feb 1;12(1):17-25.

PMID:: 23394522; [PubMed - in process]

Related citations

<< First< Prev

Page of 18

Next >Last >>

Supplemental Content

Filters: Manage Filters

PMC Images search for Palmitoylethanolamide

Figure 1

Structures of palmitoylethanolamide (C16:0), oleoylethanolamide (C18:1), palmitoylisopropylamide (C16:0) and R-palmitoyl-(2-methyl)ethanolamide (C16:0).

Effects of homologues and analogues of palmitoylethanolamide upon the inactivation of the endocannabinoid anandamide

Br J Pharmacol. 2001 August;133(8):1263-1275.
Figure 4

Inhibition of the hydrolysis by rat brain membranes of 2 μM [³H]-AEA by a series of palmitoylethanolamide analogues. Shown are means of 3–4 experiments, with no preincubation with the compounds and membranes prior to addition of [³H]-AEA. The data for palmitoylethanolamide are the same as that shown in Figure 3.

Effects of homologues and analogues of palmitoylethanolamide upon the inactivation of the endocannabinoid anandamide

Br J Pharmacol. 2001 August;133(8):1263-1275.
Figure 3

Inhibition of the hydrolysis by rat brain membranes of 2 μM [³H]-AEA by a series of palmitoylethanolamide homologues (a) C16:0–C3:0 (b) C16:0–C18:0 and C18:1. Shown are means of 3–6 experiments, with no preincubation with the compounds and membranes prior to addition of [³H]-AEA. The data for palmitoylethanolamide are the same in both graphs.

Effects of homologues and analogues of palmitoylethanolamide upon the inactivation of the endocannabinoid anandamide

Br J Pharmacol. 2001 August;133(8):1263-1275.
Figure 3

Levels of palmitoylethanolamide (PEA) in the mouse small intestine during control and croton oil-induced gut inflammation. Results are mean±s.e.mean of 4 – 5 animals for each experimental group. ^*P<0.05 vs control.

Inhibitory effect of palmitoylethanolamide on gastrointestinal motility in mice

Br J Pharmacol. 2001 November;134(5):945-950.

See more (137)...

Titles with your search terms

Therapeutic utility of palmitoylethanolamide in the treatment of neuropathic pain associated with various pathological conditions: a case series. [J Pain Res. 2012]
Therapeutic utility of palmitoylethanolamide in the treatment of neuropathic pain associated with various pathological conditions: a case series.
Hesselink JM, Hekker TA. J Pain Res. 2012; 5:437-42. Epub 2012 Oct 26.
Palmitoylethanolamide is a new possible pharmacological treatment for the inflammation associated with trauma. [Mini Rev Med Chem. 2013]
Palmitoylethanolamide is a new possible pharmacological treatment for the inflammation associated with trauma.
Esposito E, Cuzzocrea S. Mini Rev Med Chem. 2013 Feb; 13(2):237-55.
Palmitoylethanolamide versus a nonsteroidal anti-inflammatory drug in the treatment of temporomandibular joint inflammatory pain. [J Orofac Pain. 2012]
Palmitoylethanolamide versus a nonsteroidal anti-inflammatory drug in the treatment of temporomandibular joint inflammatory pain.
Marini I, Bartolucci ML, Bortolotti F, Gatto MR, Bonetti GA. J Orofac Pain. 2012 Spring; 26(2):99-104.

78 free full-text articles in PubMed Central

Treatment of chronic regional pain syndrome type 1 with palmitoylethanolamide and topical ketamine cream: modulation of nonneuronal cells. [J Pain Res. 2013]
Treatment of chronic regional pain syndrome type 1 with palmitoylethanolamide and topical ketamine cream: modulation of nonneuronal cells.
Keppel Hesselink JM, Kopsky DJ. J Pain Res. 2013; 6:239-45. Epub 2013 Mar 21.
Full Inhibition of Spinal FAAH Leads to TRPV1-Mediated Analgesic Effects in Neuropathic Rats and Possible Lipoxygenase-Mediated Remodeling of Anandamide Metabolism. [PLoS One. 2013]
Full Inhibition of Spinal FAAH Leads to TRPV1-Mediated Analgesic Effects in Neuropathic Rats and Possible Lipoxygenase-Mediated Remodeling of Anandamide Metabolism.
Starowicz K, Makuch W, Korostynski M, Malek N, Slezak M, Zychowska M, Petrosino S, De Petrocellis L, Cristino L, Przewlocka B, et al. PLoS One. 2013; 8(4):e60040. Epub 2013 Apr 3.
Palmitoylethanolamide is a disease-modifying agent in peripheral neuropathy: pain relief and neuroprotection share a PPAR-alpha-mediated mechanism. [Mediators Inflamm. 2013]
Palmitoylethanolamide is a disease-modifying agent in peripheral neuropathy: pain relief and neuroprotection share a PPAR-alpha-mediated mechanism.
Di Cesare Mannelli L, D'Agostino G, Pacini A, Russo R, Zanardelli M, Ghelardini C, Calignano A. Mediators Inflamm. 2013; 2013:328797. Epub 2013 Feb 25.